Repligen has announced a new licensing agreement with Pfizer in an effort to advance Repligen's spinal muscular atrophy (SMA) program. The work focuses on RG3039, which is a small molecule drug candidate in clinical development for the ...
Tags: Repligen, Pfizer, spinal muscular atrophy, Medicine